Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting
Rituximab has broad and increasing application in rheumatic diseases. It is known from lymphoma studies that natural killer (NK) cells can lyse rituximab-coated transformed B cells. However, the role of NK cells in mediating rituximab-induced depletion of non-malignant B cells is unknown. The purpos...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
15 September 2016
|
| In: |
Arthritis Research & Therapy
Year: 2016, Jahrgang: 18 |
| ISSN: | 1465-9913 |
| DOI: | 10.1186/s13075-016-1101-3 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s13075-016-1101-3 Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13075-016-1101-3 
|
| Verfasserangaben: | Wolfgang Merkt, Hanns-Martin Lorenz, Carsten Watzl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1566638739 | ||
| 003 | DE-627 | ||
| 005 | 20230426064438.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171221s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13075-016-1101-3 |2 doi | |
| 035 | |a (DE-627)1566638739 | ||
| 035 | |a (DE-576)496638734 | ||
| 035 | |a (DE-599)BSZ496638734 | ||
| 035 | |a (OCoLC)1340985532 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Merkt, Wolfgang |d 1984- |e VerfasserIn |0 (DE-588)1050296214 |0 (DE-627)783822316 |0 (DE-576)404501125 |4 aut | |
| 245 | 1 | 0 | |a Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting |c Wolfgang Merkt, Hanns-Martin Lorenz, Carsten Watzl |
| 264 | 1 | |c 15 September 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 21.12.2017 | ||
| 520 | |a Rituximab has broad and increasing application in rheumatic diseases. It is known from lymphoma studies that natural killer (NK) cells can lyse rituximab-coated transformed B cells. However, the role of NK cells in mediating rituximab-induced depletion of non-malignant B cells is unknown. The purpose of this study was to provide fundamental data on rituximab-mediated effects on NK cells in PBMCs without tumor cells, in order to simulate effects that could be relevant in patients with rheumatic disease. | ||
| 650 | 4 | |a B cell depletion | |
| 650 | 4 | |a CD137/41BB | |
| 650 | 4 | |a Granuloma | |
| 650 | 4 | |a Natural killer cells | |
| 650 | 4 | |a Rheumatic diseases | |
| 650 | 4 | |a Rituximab | |
| 650 | 4 | |a Vasculitis | |
| 700 | 1 | |a Lorenz, Hanns-Martin |d 1962- |e VerfasserIn |0 (DE-588)112253865 |0 (DE-627)627277845 |0 (DE-576)167601369 |4 aut | |
| 700 | 1 | |a Watzl, Carsten |e VerfasserIn |0 (DE-588)1076837557 |0 (DE-627)835380742 |0 (DE-576)175362297 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Arthritis Research & Therapy |d London : BioMed Central, 1999 |g 18(2016) Artikel-Nummer 206, 11 Seiten |h Online-Ressource |w (DE-627)326646418 |w (DE-600)2041668-4 |w (DE-576)279224648 |x 1465-9913 |7 nnas |a Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting |
| 773 | 1 | 8 | |g volume:18 |g year:2016 |a Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13075-016-1101-3 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s13075-016-1101-3 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171221 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1076837557 |a Watzl, Carsten |m 1076837557:Watzl, Carsten |d 910000 |d 911600 |e 910000PW1076837557 |e 911600PW1076837557 |k 0/910000/ |k 1/910000/911600/ |p 3 |y j | ||
| 998 | |g 112253865 |a Lorenz, Hanns-Martin |m 112253865:Lorenz, Hanns-Martin |d 910000 |d 910100 |e 910000PL112253865 |e 910100PL112253865 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 1050296214 |a Merkt, Wolfgang |m 1050296214:Merkt, Wolfgang |d 910000 |d 910100 |e 910000PM1050296214 |e 910100PM1050296214 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1566638739 |e 2990795340 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1566638739"],"doi":["10.1186/s13075-016-1101-3"]},"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"15 September 2016"}],"relHost":[{"disp":"Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental settingArthritis Research & Therapy","pubHistory":["1.1999 -"],"recId":"326646418","note":["Gesehen am 24. Mai 2016"],"id":{"zdb":["2041668-4"],"issn":["1465-9913","1478-6362"],"eki":["326646418"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"origin":[{"dateIssuedDisp":"1999-","publisherPlace":"London","publisher":"BioMed Central","dateIssuedKey":"1999"}],"title":[{"title_sort":"Arthritis Research & Therapy","title":"Arthritis Research & Therapy"}],"titleAlt":[{"title":"Arthritis Research"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"year":"2016","volume":"18","text":"18(2016) Artikel-Nummer 206, 11 Seiten"}}],"person":[{"family":"Merkt","display":"Merkt, Wolfgang","given":"Wolfgang","role":"aut"},{"family":"Lorenz","display":"Lorenz, Hanns-Martin","given":"Hanns-Martin","role":"aut"},{"role":"aut","family":"Watzl","display":"Watzl, Carsten","given":"Carsten"}],"title":[{"title_sort":"Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting","title":"Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting"}],"note":["Gesehen am 21.12.2017"],"recId":"1566638739","name":{"displayForm":["Wolfgang Merkt, Hanns-Martin Lorenz, Carsten Watzl"]}} | ||
| SRT | |a MERKTWOLFGRITUXIMABI1520 | ||